GB1211 (Galectin-3 inhibitor)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GB1211 (Galectin-3 inhibitor), covering 2024-04-12 to 2024-04-12. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). [Phase 1, Phase 2]